Gilde acquires Viroclinics

Gilde invested in the company via its Gilde Healthcare Services I fund, a €50m vehicle launched in 2009. The firm acquired its stake in Viroclinics from Erasmus University Medical Centre, allowing the institute to fully exit from the CRO.

The acquisition follows on the heels of Gilde's latest fund close at the end of November last year. Gilde Healthcare III held its final close on its target of €145m after three years on the road.

Company
Viroclinics span out from the Erasmus University Medical Centre in 2001. The company is headquartered in Rotterdam and employs around 50 staff.

The Dutch CRO provides the biopharmaceutical industry with diagnostic and pre-clinical studies for vaccines and antiviral treatments. It also takes part in drug development for the prevention and treatment of viruses.

People
Bob van Gemen is the CEO of Viroclinics. Jasper van Gorp is a partner at Gilde.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Buyouts
• Netherlands
• Gilde Investment Management